These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25269480)

  • 1. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
    Chinen Y; Kuroda J; Shimura Y; Nagoshi H; Kiyota M; Yamamoto-Sugitani M; Mizutani S; Sakamoto N; Ri M; Kawata E; Kobayashi T; Matsumoto Y; Horiike S; Iida S; Taniwaki M
    Cancer Res; 2014 Dec; 74(24):7418-29. PubMed ID: 25269480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma.
    Tatekawa S; Chinen Y; Ri M; Narita T; Shimura Y; Matsumura-Kimoto Y; Tsukamoto T; Kobayashi T; Kawata E; Uoshima N; Taki T; Taniwaki M; Handa H; Iida S; Kuroda J
    Br J Haematol; 2017 Aug; 178(4):534-546. PubMed ID: 28439875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.
    Maegawa S; Chinen Y; Shimura Y; Tanba K; Takimoto T; Mizuno Y; Matsumura-Kimoto Y; Kuwahara-Ota S; Tsukamoto T; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Exp Hematol; 2018 Mar; 59():72-81.e2. PubMed ID: 29287939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
    Isa R; Horinaka M; Tsukamoto T; Mizuhara K; Fujibayashi Y; Taminishi-Katsuragawa Y; Okamoto H; Yasuda S; Kawaji-Kanayama Y; Matsumura-Kimoto Y; Mizutani S; Shimura Y; Taniwaki M; Sakai T; Kuroda J
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
    Shimura Y; Kuroda J; Ri M; Nagoshi H; Yamamoto-Sugitani M; Kobayashi T; Kiyota M; Nakayama R; Mizutani S; Chinen Y; Sakamoto N; Matsumoto Y; Horiike S; Shiotsu Y; Iida S; Taniwaki M
    Mol Cancer Ther; 2012 Dec; 11(12):2600-9. PubMed ID: 23012246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide-dependent Kinase-1 (PDPK1) regulates serum/glucocorticoid-regulated Kinase 3 (SGK3) for prostate cancer cell survival.
    Nalairndran G; Hassan Abdul Razack A; Mai CW; Fei-Lei Chung F; Chan KK; Hii LW; Lim WM; Chung I; Leong CO
    J Cell Mol Med; 2020 Oct; 24(20):12188-12198. PubMed ID: 32926495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.
    Katsuragawa-Taminishi Y; Mizutani S; Kawaji-Kanayama Y; Onishi A; Okamoto H; Isa R; Mizuhara K; Muramatsu A; Fujino T; Tsukamoto T; Shimura Y; Taniwaki M; Miyagawa-Hayashino A; Konishi E; Kuroda J
    Cancer Sci; 2023 Dec; 114(12):4691-4705. PubMed ID: 37840379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage-Associated PGK1 Phosphorylation Promotes Aerobic Glycolysis and Tumorigenesis.
    Zhang Y; Yu G; Chu H; Wang X; Xiong L; Cai G; Liu R; Gao H; Tao B; Li W; Li G; Liang J; Yang W
    Mol Cell; 2018 Jul; 71(2):201-215.e7. PubMed ID: 30029001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDPK1/RSK2 signaling pathway as the possible therapeutic target for multiple myeloma.
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():180-4. PubMed ID: 30615342
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotic gene regulation by the N-MYC-WDR5-PDPK1 nexus.
    Streeter SA; Williams AG; Evans JR; Wang J; Guarnaccia AD; Florian AC; Al-Tobasei R; Liu Q; Tansey WP; Weissmiller AM
    BMC Genomics; 2024 Apr; 25(1):360. PubMed ID: 38605297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR‑16‑2‑3p inhibits cell proliferation and migration and induces apoptosis by targeting PDPK1 in maxillary primordium mesenchymal cells.
    Han T; Wu N; Wang Y; Shen W; Zou J
    Int J Mol Med; 2019 Mar; 43(3):1441-1451. PubMed ID: 30664182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses.
    Tu Y; Gardner A; Lichtenstein A
    Cancer Res; 2000 Dec; 60(23):6763-70. PubMed ID: 11118064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
    Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
    Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
    Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
    Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
    Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
    Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.
    Kulkarni MS; Daggett JL; Bender TP; Kuehl WM; Bergsagel PL; Williams ME
    Leukemia; 2002 Jan; 16(1):127-34. PubMed ID: 11840272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells.
    Mäemets-Allas K; Belitškin D; Jaks V
    Biochem Biophys Res Commun; 2016 May; 474(1):118-125. PubMed ID: 27103434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.